In an un­usu­al piv­ot, Swiss biotech Basilea looks to ditch can­cer pipeline in fa­vor of — an­ti-in­fec­tives?

On­col­o­gy has been the sin­gle largest dri­ver of rev­enues across bio­phar­ma for years now, and you’re more like­ly than ever to see a com­pa­ny ditch all oth­er plans to chase that white rab­bit. But a Swiss biotech is bet­ting its fu­ture on a per­pen­dic­u­lar path, opt­ing to ditch its on­col­o­gy as­sets in­stead.

Switzer­land-based Basilea will look to of­fload its on­col­o­gy pipeline in part or in full as part of a re­or­ga­ni­za­tion of its R&D pipeline around an­ti-in­fec­tives, in­clud­ing its two ap­proved drugs in that space, the biotech said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER